ClinicalTrials.gg
TerminatedNCT04303858Updated Jun 2, 2026

A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors

A Phase 1 interventional study of Eciskafusp Alfa and Atezolizumab in Solid Tumors, sponsored by Hoffmann-La Roche. Terminated at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
After risk/benefit analysis, there was a very low probability (4.4%) of meeting the prespecified gating criteria for the Objective Response Rate at the final analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an entry-into-human study and will assess the effects of eciskafusp alfa (RO7284755) as a single agent and in combination with atezolizumab in adult participants with solid tumors considered responsive to checkpoint inhibition blockade. The maximum duration in the study for each participant will be up to 28 months.

Read the detailed description

The study consists of three parts: dose-escalation of eciskafusp alfa as a single agent (Part 1), dose-escalation of eciskafusp alfa in combination with atezolizumab (Part 2), and extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab (Part 3).

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced/unresectable or disease
  • No standard of care (SoC) (approved) treatments are available for the participant, or the participant cannot tolerate such treatments
  • , as defined by version 1.1 (RECIST v1.1)
  • Performance Status 0 to 1
  • of >=12 weeks
  • Consent to provide an sample
  • Adequate cardiovascular, hematological, coagulative, hepatic and renal function

Exclusion criteria

Exclusion Criteria:

  • Rapid disease progression or suspected hyperprogression or threat to vital organs or critical anatomical sites requiring urgent alternative medical intervention
  • Untreated central nervous system (CNS)
  • Treated asymptomatic
  • Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >= 2 weeks before Cycle1 Day 1 (C1D1)
  • Active or history of carcinomatous meningitis/
  • Uncontrolled tumor-related pain or symptomatic hypercalcemia
  • Concurrent second
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
  • Episode of significant cardiovascular/cerebrovascular acute disease within 28 days before study treatment administration
  • Active or uncontrolled infections
  • Known infection
  • virus (HBV) or virus infection
  • Adverse events related to any prior radiotherapy, chemotherapy, targeted therapy, CPI therapy or surgical procedure must have resolved to Grade \<=1, except alopecia Grade 2 peripheral neuropathy, and hypothyroidism and/or hypopituitarism on a stable dosage of hormone replacement therapy
  • Participants with bilateral pleural effusion
  • Major surgery or significant traumatic injury \< 28 days before study treatment administration or anticipation of the need for major surgery during study treatment
  • Known allergy or to any component of the formulations of the IMPs to be administered, including but not limited to hypersensitivity to Chinese hamster ovary cell products or other recombinant or humanized antibodies
  • History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins
  • Previous treatment with Interleukin-2 (IL-2)/Interleukin-5 (IL-15)-like cytokines. IL-2/IL-15 use as an adjunct treatment component for adoptive cell therapy is permitted. In Part 3, patients who have received adoptive cell therapy such as tumor-infiltrating lymphocytes (TIL) are excluded.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Eciskafusp Alfa as a Single Agent

    Part 1: Dose-escalation of eciskafusp alfa as a single agent. eciskafusp alfa will be either an intravenous administration (IV) or subcutaneous administration (SC) in multiple-ascending doses.

    Drug: Eciskafusp Alfa

  • Experimental
    Eciskafusp Alfa in Combination with Atezolizumab

    Part 2: Dose-escalation of eciskafusp alfa in combination with atezolizumab.

    Drug: Eciskafusp Alfa · Drug: Atezolizumab

  • Experimental
    Eciskafusp Alfa as a Single Agent and/or with Atezolizumab

    Part 3: Extension of eciskafusp alfa as a single agent and/or in combination with atezolizumab.

    Drug: Eciskafusp Alfa · Drug: Atezolizumab

Interventions

  • DrugEciskafusp Alfa

    Participants will be administered eciskafusp alfa in different schedules.

    Also known as: RO7284755

  • Participants will be administered 1200 mg of atezolizumab once every 3 weeks.

    Also known as: Tecentriq

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events in Part 1 and Part 2

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From randomization until end of Part 1 and Part 2 (up to approximately 1.5 months)

  2. Percentage of Participants with Dose-Limiting Toxicities in Part 1 and Part 2

    A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during Part 1 and Part 2 only, and is considered by the Investigator to be related to eciskafusp alfa or to the combination of eciskafusp alfa and atezolizumab. In Part 2, expected toxicities that are, in the opinion of the Investigator, entirely attributable to atezolizumab, will not be considered DLTs.

    Time frame: From randomization up to day 14 (Part 1) or day 28 (Part 2)

  3. Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Part 3

    Objective response rate (ORR) was defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).

    Time frame: From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)

  4. Recommended Dose for Extension (RDE) of Eciskafusp Alfa in Parts 1 and 2

    Time frame: From randomization up to day 14 (Part 1) or day 28 (Part 2)

Secondary outcomes

  1. Investigator Assessed Objective Response Rate according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Parts 1 and 2

    ORR was defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).

    Time frame: From randomization until end of Part 1 and Part 2 (up to approximately 1.5 months)

  2. Percentage of Participants with Adverse Events in Part 3

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)

  3. Disease Control Rate in Part 3

    The disease control rate was defined as proportion of participants being either responder or in 'stable disease' (SD). To classify a response as SD, measurements will have to be classified as stable (according to RECIST v1.1) at least once at a minimum of 4 weeks after study entry.

    Time frame: From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)

  4. Duration of Response in Part 3

    Duration of response will be calculated for 'responder' participants (i.e. best \[confirmed\] overall response of CR or PR) and will be defined as the time from first occurrence of a documented response until the time of documented disease progression or death (death within 30 days from last study treatment) from any cause, whichever occurs first.

    Time frame: From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)

  5. Progression-free survival (PFS) in Part 3

    Progression-free survival was defined as the time from first dose of study treatment to the first occurrence of documented disease progression (based on RECIST 1.1 Investigator's assessment) or death from any cause, whichever occurs first.

    Time frame: From start of extension phase until disease progression, drug discontinuation, withdrawal or death (up to approximately 26 months)

  6. Change from Baseline in Antidrug Antibody (ADA) to Eciskafusp Alfa

    Time frame: Up to 28 months

  7. Percentage of Partcipants with ADAs to Eciskafusp Alfa

    Time frame: Up to 28 months

  8. Area Under the Curve (AUC) for Eciskafusp Alfa

    Time frame: Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)

  9. Minimum Concentration (Cmin) for Eciskafusp Alfa

    Time frame: Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)

  10. Maximum Concentration (Cmax) for Eciskafusp Alfa

    Time frame: Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)

  11. Clearance (CL) for Eciskafusp Alfa

    Time frame: Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)

  12. Volume of Distribution at Steady-State Conditions (Vss) for Eciskafusp Alfa

    Time frame: Predose, C1 Days 1, 2, 3, 5, 8, 9, 10, 12, 15, 16, 17, and 19; C2 Days 1, 2, 8, 9, 10, 12, 15, and 16; C3 Days 1, 2, 3, and 8; C4 Days 1 and 2; C5 Days1, 2, and 8; and days 1 and 2 for any subsequent cycles (Up to 28 months)

  13. Percentage of Immune and Tumor Cells with Positive Programmed Cell Death-1 (PD-1) and Programmed Cell Death-Ligand 1 (PD-L1) Expression in the Tumor Microenvironment (TME)

    Time frame: Baseline

  14. Percentage of Immune Cells with CD8+ PD1+ and CD8+ PD1+ TCF7+ Expression

    Time frame: Baseline

  15. Blood Tumor Mutational Burden

    Blood tumor mutational burden is defined as the number of genetic mutations per megabase (1,000,000 bases).

    Time frame: Baseline

  16. Change from Baseline in Percentage of Immune Cell Subsets

    Immune cells include NK, CD8, and Treg cells

    Time frame: Baseline to End of Treatment (up to approximately 28 months)

  17. Change from Baseline in Percentage of Immune Markers

    Immune markers include PD-1, PD-L1, sCD25, cytokines, etc...

    Time frame: Baseline to End of Treatment (up to approximately 28 months)

07

Study locations

12 sites
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Herlev Hospital
    Herlev, 2730, Denmark
  • Rigshospitalet
    København Ø, 2100, Denmark
  • NKI/AvL
    Amsterdam, 1066 CX, Netherlands
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie
    Warsaw, 02-781, Poland
  • Clinica Universitaria de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona
    Barcelona, 08035, Spain
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Oct 2025, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 11, 2020
StartActual
May 4, 2020
Primary completionActual
Oct 2, 2025
CompletionActual
Oct 2, 2025
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04303858
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 11, 2020
Start date
May 4, 2020
Primary completion
Oct 2, 2025
Completion
Oct 2, 2025
Last update
Jun 2, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion